Metonitazene
Metonitazene is an analgesic compound related to etonitazene,[2][3] which was first reported in 1957,[4] and has been shown to have approximately 1000 times the potency of morphine by central routes of administration,[5] but if used orally it has been shown to have approximately 10 times the potency of morphine.[6] Its effects are similar to other opioids such as fentanyl and heroin, including analgesia, euphoria, and sleepiness.[6][7] Adverse effects include vomiting, and respiratory depression that can potentially be fatal.[8] Because of high dependency potential and dangerous adverse effects it has never been introduced into pharmacotherapy. It is instead commonly used in the illicit manufacture of counterfeit oxycodone opioid pills.[9] Legal statusIn the United States, metonitazene is a Schedule I controlled substance under the Controlled Substances Act. Metonitazene is not controlled under the 1971 Convention on Psychotropic Substances; however, in many countries possession or intent to sell for human consumption might be prosecuted under several analog acts. Metonitazene became a Class A drug in the UK on 20th March 2024. See alsoReferences
|